Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non‐small cell lung cancer

Byrne, Michael; Phillips, Michael; Powell, Anne; Cameron, F.; Joseph, David; Spry, Nigel; Dewar, Joanna; Hazel, G. Van; Buck, Martin; Lund, Harold G.; Melker, Y. De; Newman, Mark

doi:10.1111/j.1445-5994.2005.00837.x

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We report an incidence of 1.8% of AML in our study cohort. The most common chromosomal translocation in chemotherapy associated AML is t (11:23), however t (3;21), inv (16) The absolute survival benefit of concurrent CRT in LA-NSCLC is well known in the literature. The 2 and 5 years absolute survival benefit of 4% and 2.2% compared to sequential CRT was reported in the meta-analysis by Aupérin et al (8).…”

Section: Discussionmentioning

confidence: 99%

“…Platinum-based chemotherapy has been extensively studied in combination with radiation therapy for localised unresectable NSCLC. Older regimens include MVP (mitomycin C, vindesine and cisplatin) (9)(10)(11), cisplatin/ vinblastine (12,13), and cisplatin/etoposide (14), newer agents include cisplatin/taxanes (15), cisplatin/gemcitabine (16,17), and platinum/irinotecan (18).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up

Abbas¹,

Ayoola²,

Padman³

et al. 2019

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: The preferred management of patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemo-radiotherapy (CRT). Acute CRT-related toxicities are well defined, however, less is known about late toxicities. The aim of the study was to examine the outcomes and late toxicities in Stage III NSCLC treated with CRT. Methods: A retrospective review of the data from patients with stage III NSCLC treated with CRT was performed between May 2000 and June 2010. Demographics, tumour and treatment characteristics, toxicities and survival data were examined from hospital records of the patients. Progression free survival (PFS) and overall survival (OS) were evaluated by standard Kaplan-Meier survival curves. The censor date was set on 31 October 2016. Results: Sixty-three patients were identified with a median age of 66.6 years [interquartile range (IQR) 57.2-72.1], two-third (n=41, 65.1%) were male, majority were current or ex-smokers (n=52, 82.5%), 42 (66.7%) patients had stage IIIB disease and 21 (33.3%) had stage IIIA disease. The most common histologic subtype was adenocarcinoma 30 (47.6%). The median PFS and OS of the whole population was 10.6 months (95% CI, 4.1-17.3 months) and 21 months (95% CI, 12.7-29.3 months) respectively.The 5-year OS rates for stage IIIA and IIIB were 24% and 16% respectively. The 1-, 3-and 5-year OS rates for all patients were 63.5%, 46% and 18.7% respectively. Acute grade 3 and 4 toxicities included 28 haematological and 17 non-haematological events. The incidence of late toxicities was 58.9%.Thirty-three events of late grade 3 and 4 toxicities were recorded. The most common late toxicity was symptomatic radiation-induced pulmonary fibrosis (39.3%), others include ototoxicity (7.1%), persistent dysphagia (7.1%) and one case of acute myeloid leukaemia. All patients that were alive at the censor date had developed radiation-induced fibrosis with associated symptoms of respiratory insufficiency. Conclusions:The 5-year OS of patients with stage III NSCLC treated with CRT was in keeping with survival figures reported from prospective clinical trials. There is, however, significant morbidity associated with long-term survival and this should be taken into account when making informed treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up

Abbas¹,

Ayoola²,

Padman³

et al. 2019

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

Efficacy of C ombined G emcitabine/Cisplatin C hemotherapy for Locally Advanced or Metastatic Urothelial Cancer

et al. 2006

View full text Add to dashboard Cite

Purpose: W e wanted to determine and report on the outcome of combined gemcitabine/cisplatin chemotherapy for patients suffering with locally advanced or metastatic urothelial cancer.Materials and Methods: Between July 1999 and December 2004, 43 selected patients were enrolled in this study. Group 1 (the adjuvant chemotherapy group) had undergone radical surgery with removal of evident tumor from the following primary sites: bladder (n=8), renal pelvis (n=7) and ureter (n=3). Group 2 (the salvage chemotherapy group) had undergone palliative surgery with a remnant tumor at the following primary sites; bladder (n=23) and renal pelvis (n=2). All the patients were given gemcitabine/ciplatin and they evaluated for the therapeutic effect and toxicity. The patients were initially treated with gemcitabine 1000 mg/m 2 intravenously for 30 minutes on days 1, 8 and 15 of a 28-day cycle, and cisplatin 70 mg/m 2 was administered intravenously on day 1 using prehydration measures.Results: Group 1: The median follow-up period was 16.5 months. The mean age was 63 years (males: 15 cases, females: 3 cases), and eleven patients (61% ) remained alive. The estimated median relapse-free survival period and 2-year survival rate were 24 months and 63% , respectively. Group 2: the median follow-up period was 20 months, the mean patient age was 63.8 years (males: 22 cases, females: 3 cases), and nine patients (36% ) remained alive. The overall response and 2-year survival rates were 36% and 43%, respectively. Toxicities: Grade 3 toxicities developed in 14 cycles during the total 232 cycles. Grade 4 toxicity did not occur.Conclusions: The results of this study confirm that adjuvant and salvage chemotherapy with using gemcitabine and cisplatin is tolerable and safe.

show abstract

Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non‐small cell lung cancer

Abstract: These results are equivalent to other studies using induction chemotherapy prior to concurrent chemoradiotherapy. Response to induction chemotherapy may have major prognostic significance.

Cited by 2 publications

References 24 publications

Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up

Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up

Efficacy of C ombined G emcitabine/Cisplatin C hemotherapy for Locally Advanced or Metastatic Urothelial Cancer

Contact Info

Product

Resources

About